Clinical Trial Update: Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating niraparib in combination with dostarlimab for patients with MMR-D/MSI-H colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Dostarlimab (Jemperli) (dostarlimab)
• Niraparib (Zejula) (Niraparib)

Snippet

Sponsor: Ibrahim Halil Sahin | Conditions: MMR-D/MSI-H Colorectal Cancers | Phase 2 | Status: WITHDRAWN